Government-Owned Inventions; Availability for Licensing, 51627-51628 [E6-14353]
Download as PDF
<![CDATA[
51627
Federal Register / Vol. 71, No. 168 / Wednesday, August 30, 2006 / Notices
Average Burden Hours per Response:
.7445.
Estimated Total Annual Burden
Hours Requested: 169.75.
The annualized cost to respondents is
$7,129.50.
There are no Capital Costs to report.
There are no Operating or Maintenance
Costs to report.
Estimated
number of respondents
Estimated
number of
responses per
respondent
State Tobacco Control Manager .....................................................................
State Quitline Administrator .............................................................................
State Quitline Service Provider .......................................................................
State Quitline Partner ......................................................................................
NAQC Representative .....................................................................................
51
51
19
102
5
1
1
1
1
1
1.00
1.00
.75
.50
.50
51.00
51.00
14.25
51.00
2.50
Total ..........................................................................................................
228
........................
........................
169.75
jlentini on PROD1PC65 with NOTICES
Type of respondents
Request for Comments: Written
comments and/or suggestions from the
public and affected agencies are invited
on one or more of the following points:
(1) Whether the proposed collection of
information is necessary for the proper
performance of the function of the
agency, including whether the
information will have practical utility;
(2) the accuracy of the agency’s estimate
of the burden of the proposed collection
of information, including the validity of
the methodology and assumptions used;
(3) ways to enhance the quality, utility,
and clarity of the information to be
collected; and (4) ways to minimize the
burden of the collection of information
on those who are to respond, including
the use of appropriate automated,
electronic, mechanical, or other
technological collection techniques or
other forms of information technology.
Direct Comments to OMB: Written
comments and/or suggestions regarding
the item(s) contained in this notice,
especially regarding the estimated
public burden and associated response
time, should be directed to the: Office
of Management and Budget, Office of
Regulatory Affairs, New Executive
Office Building, Room 10235,
Washington, DC 20503, Attention: Desk
Officer for NIH. To request more
information on the proposed project or
to obtain a copy of the data collection
plans and instruments, contact Candace
Deaton, M.P.A., Project Officer, National
Cancer Institute, Cancer Information
Service, 6116 Executive Blvd., Suite
3056A, Room 3028, Rockville, MD
20892 or call non-toll-free number 301–
594–9072 or e-mail your request,
including your address to:
deatonc@mail.nih.gov.
Comments Due Date: Comments
regarding this information collection are
best assured of having their full effect if
received within 30-days of the date of
this publication.
VerDate Aug<31>2005
16:39 Aug 29, 2006
Jkt 208001
Dated: August 21, 2006.
Rachelle Ragland Greene,
NCI Project Clearance Liaison, National
Institutes of Health.
[FR Doc. E6–14354 Filed 8–29–06; 8:45 am]
BILLING CODE 4101–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions;
Availability for Licensing
National Institutes of Health,
Public Health Service, HHS.
ACTION: Notice.
AGENCY:
SUMMARY: The inventions listed below
are owned by an agency of the U.S.
Government and are available for
licensing in the U.S. in accordance with
35 U.S.C. 207 to achieve expeditious
commercialization of results of
federally-funded research and
development. Foreign patent
applications are filed on selected
inventions to extend market coverage
for companies and may also be available
for licensing.
ADDRESSES: Licensing information and
copies of the U.S. patent applications
listed below may be obtained by writing
to the indicated licensing contact at the
Office of Technology Transfer, National
Institutes of Health, 6011 Executive
Boulevard, Suite 325, Rockville,
Maryland 20852–3804; telephone: 301/
496–7057; fax: 301/402–0220. A signed
Confidential Disclosure Agreement will
be required to receive copies of the
patent applications.
ABCB1 Genotyping To Predict
Paclitaxel Toxicity
Description of Technology: Paclitaxel
has been a frontline chemotherapeutic
drug used for the treatment of various
cancers including metastatic breast
cancer and ovarian cancer. Its use has
PO 00000
Frm 00062
Fmt 4703
Sfmt 4703
Average
burden hours
per response
Estimated total
annual burden
hours
requested
successfully prolonged patient survival.
A major drawback of paclitaxel is the
cytotoxic side-effects that are associated
with it such as myologenic and
neurogenic toxicities. The degree of
such toxicities varies with individual
patients. Predicting the extent of such
toxicities following paclitaxel treatment
will immensely help in defining optimal
treatment schedules for each individual
patient. Concurrently, it will
significantly improve patient quality of
life.
This technology describes the
identification of three genetic markers
in the ABCB1 (MDR–1, P-glycoprotein)
gene that can be used to predict the
degree of neutropenia and peripheral
neuropathy that an individual will
experience following paclitaxel
treatment. These markers were
identified using DNA from blood
samples of cancer patients undergoing
paclitaxel treatment. This technology
can be developed into a routine blood
test to identify patient subsets that are
more susceptible to paclitaxel treatment
associated neutropenia and neuropathy.
Applications:
1. Three novel genetic markers that
can predict extent of paclitaxel
associated toxicities.
2. A screening test based on ABCB1
genotype profiling using patient blood
samples that predicts paclitaxel
associated neutropenia and peripheral
neuropathy.
Market: The diagnostic market is
worth about $3 billion by 2007 and
estimated to grow further.
Development Status:
1. The technology is a pilot study
currently in the pre-clinical stage of
development.
2. A prospective ABCB1 genotype
directed clinical trial is foreseen in the
near future.
Inventors: William D. Figg (NCI), Alex
Sparreboom (NCI), Tristan M. Sissung
(NCI), Stephan Mielke (NCI), et al.
E:\FR\FM\30AUN1.SGM
30AUN1
51628
Federal Register / Vol. 71, No. 168 / Wednesday, August 30, 2006 / Notices
jlentini on PROD1PC65 with NOTICES
Publication: T. M Sissung et al.
Association of ABCB1 genotypes with
paclitaxel-mediated neutropenia and
peripheral neuropathy, To be submitted
to Clinical Pharmacology and Therapy.
Patent Status: U.S. Provisional
Application No. 60/807,453 filed 14 Jul
2006 (HHS Reference No. E–237–2006/
0–US–01).
Licensing Status: Available for nonexclusive or exclusive licensing.
Licensing Contact: David Lambertson,
PhD; 301/435–4632;
lambertsond@od.nih.gov.
Collaborative Research Opportunity:
The NCI Medical Oncology Branch is
seeking statements of capability or
interest from parties interested in
collaborative research to further
develop, evaluate, or commercialize
ABCB1 genotyping to predict paclitaxel
toxicity. Please contact Betty Tong, PhD
at 301–496–0477, tongb@mail.nih.gov
for more information.
Use of Grape Skin Extracts as AntiCancer Agents
Description of Technology: The
invention describes anti-tumor effects of
extracts from grape skins. Grape skin
extract and derivatives may therefore be
useful as preventive or therapeutic
agents against tumor development.
Literature indicates that grape and red
wine consumption may be inversely
associated with prostate cancer risk.
Moreover, to date there are no known
grape skin extract-associated toxicities
described. The current invention
discloses that grape skin extract, or
purified fractions thereof, inhibited
metastatic growth in human prostate
transformed cell lines. Specifically,
grape skin extract induced cellular
apoptosis via inhibition of the
phosphatidylinositol 3-kinase (PI3-K)/
Akt survival pathway.
Historically, anti-tumor effects of
grapes were mainly attributed to
resveratrol, a phytoalexin present in
grapes, nuts and wild berries. However,
resveratrol’s mechanism of anti-tumor
action is distinct from that of grape skin
extract, in that it arrests cell cycle
division without significant induction
of apoptosis.
The current invention also provides
for methods of treating patients with
prostate cancer or persons at risk for
developing prostate cancer with
compositions that include grape skin
extract or active anti-tumor fractions
thereof.
Development Status: Pre-clinical
stage.
Inventors: Tamaro Hudson and Jeffrey
E. Green (NCI).
Patent Status: U.S. Provisional
Application No. 60/789,181 filed 03
VerDate Aug<31>2005
16:39 Aug 29, 2006
Jkt 208001
April 2006 (HHS Reference No. E–179–
2006/0–US–01).
Licensing Status: Available for nonexclusive or exclusive licensing.
Licensing Contact: David A.
Lambertson, PhD; 301–435–4632;
lambertsond@od.nih.gov.
Collaborative Research Opportunity:
The NCI’s Laboratory of Cell Regulation
and Carcinogenesis is seeking
statements of capability or interest from
parties interested in collaborative
research to further develop, evaluate, or
commercialize this technology. Please
contact Patrick Twomey, PhD at 301–
496–0477 or twomeyp@mail.nih.gov for
more information.
Dated: August 23, 2006.
Steven M. Ferguson,
Director, Division of Technology Development
and Transfer, Office of Technology Transfer,
National Institutes of Health.
[FR Doc. E6–14353 Filed 8–29–06; 8:45 am]
September 13, 2006, 6 p.m., Doubletree
Hotel, 8120 Wisconsin Ave., Bethesda,
MD, 20814 which was published in the
Federal Register on July 25, 2006. 71 FR
42098.
The meeting notice is amended to
reflect the change in hotel from the
Doubletree Hotel, 8120 Wisconsin Ave.,
Bethesda, MD 20814 to the Clarion
Hotel, 8400 Wisconsin Ave., Bethesda,
MD 20814. The meeting is closed to the
public.
Dated: August 22, 2006.
Anna Snouffer,
Acting Director, Office of Federal Advisory
Committee Policy.
[FR Doc. 06–7229 Filed 8–29–06; 8:45 am]
BILLING CODE 4140–01–M
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
BILLING CODE 4140–01–P
National Institutes of Health
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Center on Minority Health and
Health Disparities; Amended Notice of
Meeting
National Institutes of Health
National Cancer Institute; Amended
Notice of Meeting
Notice is hereby given of a change in
the meting of the National Cancer
Institute Special Emphasis Panel,
September 11, 2006, 5 p.m. to
September 13, 2006, 5 p.m. Doubletree
Hotel Bethesda, 8120 Wisconsin Ave.,
Bethesda, MD, 20814 which was
published in the Federal Register on
July 25, 2006, 71 FR 42099.
The meeting notice is amended to
reflect the change in hotel from the
Doubletree Hotel, 8120 Wisconsin Ave.,
Bethesda, MD 20814 to the Clarion
Hotel, 8400 Wisconsin Ave., Bethesda,
MD 20814. The meeting is closed to the
public.
Dated: August 22, 2006.
Anna Snouffer,
Acting Director, Office of Federal Advisory
Committee Policy.
[FR Doc. 06–7228 Filed 8–29–06; 8:45 am]
BILLING CODE 4140–01–M
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Cancer Institute; Amended
Notice of Meeting
Notice is hereby given of a change in
the meeting of the National Cancer
Institute Special Emphasis Panel,
September 11, 2006, 5 p.m. to
PO 00000
Frm 00063
Fmt 4703
Sfmt 4703
Notice is hereby given of a change in
the meeting of the National Advisory
Council on Minority Health and Health
Disparities, September 12, 2006, 8:30
a.m. to September 12, 2006, 5 p.m.,
National Institutes of Health, Two
Democracy Plaza, 6707 Democracy
Boulevard, Bethesda, MD, 20892 which
was published in the Federal Register
on August 18, 2006, 71 FR 47817.
The meeting location changed to the
Bethesda Marriott, 5151 Pooks Hill Rd.,
Bethesda, Maryland 20814. The meeting
is partially closed to the public.
Dated: August 23, 2006.
Anna Snouffer
Acting Director, Office of Federal Advisory
Committee Policy.
[FR Doc. 06–7227 Filed 8–29–06; 8:45 am]
BILLING CODE 4140–01–M
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Eye Institute; Notice of Closed
Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. Appendix 2), notice
is hereby given of the following
meetings.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
E:\FR\FM\30AUN1.SGM
30AUN1
]]>Agencies
[Federal Register Volume 71, Number 168 (Wednesday, August 30, 2006)]
[Notices]
[Pages 51627-51628]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E6-14353]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions; Availability for Licensing
AGENCY: National Institutes of Health, Public Health Service, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The inventions listed below are owned by an agency of the U.S.
Government and are available for licensing in the U.S. in accordance
with 35 U.S.C. 207 to achieve expeditious commercialization of results
of federally-funded research and development. Foreign patent
applications are filed on selected inventions to extend market coverage
for companies and may also be available for licensing.
ADDRESSES: Licensing information and copies of the U.S. patent
applications listed below may be obtained by writing to the indicated
licensing contact at the Office of Technology Transfer, National
Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville,
Maryland 20852-3804; telephone: 301/496-7057; fax: 301/402-0220. A
signed Confidential Disclosure Agreement will be required to receive
copies of the patent applications.
ABCB1 Genotyping To Predict Paclitaxel Toxicity
Description of Technology: Paclitaxel has been a frontline
chemotherapeutic drug used for the treatment of various cancers
including metastatic breast cancer and ovarian cancer. Its use has
successfully prolonged patient survival. A major drawback of paclitaxel
is the cytotoxic side-effects that are associated with it such as
myologenic and neurogenic toxicities. The degree of such toxicities
varies with individual patients. Predicting the extent of such
toxicities following paclitaxel treatment will immensely help in
defining optimal treatment schedules for each individual patient.
Concurrently, it will significantly improve patient quality of life.
This technology describes the identification of three genetic
markers in the ABCB1 (MDR-1, P-glycoprotein) gene that can be used to
predict the degree of neutropenia and peripheral neuropathy that an
individual will experience following paclitaxel treatment. These
markers were identified using DNA from blood samples of cancer patients
undergoing paclitaxel treatment. This technology can be developed into
a routine blood test to identify patient subsets that are more
susceptible to paclitaxel treatment associated neutropenia and
neuropathy.
Applications:
1. Three novel genetic markers that can predict extent of
paclitaxel associated toxicities.
2. A screening test based on ABCB1 genotype profiling using patient
blood samples that predicts paclitaxel associated neutropenia and
peripheral neuropathy.
Market: The diagnostic market is worth about $3 billion by 2007 and
estimated to grow further.
Development Status:
1. The technology is a pilot study currently in the pre-clinical
stage of development.
2. A prospective ABCB1 genotype directed clinical trial is foreseen
in the near future.
Inventors: William D. Figg (NCI), Alex Sparreboom (NCI), Tristan M.
Sissung (NCI), Stephan Mielke (NCI), et al.
[[Page 51628]]
Publication: T. M Sissung et al. Association of ABCB1 genotypes
with paclitaxel-mediated neutropenia and peripheral neuropathy, To be
submitted to Clinical Pharmacology and Therapy.
Patent Status: U.S. Provisional Application No. 60/807,453 filed 14
Jul 2006 (HHS Reference No. E-237-2006/0-US-01).
Licensing Status: Available for non-exclusive or exclusive
licensing.
Licensing Contact: David Lambertson, PhD; 301/435-4632;
lambertsond@od.nih.gov.
Collaborative Research Opportunity: The NCI Medical Oncology Branch
is seeking statements of capability or interest from parties interested
in collaborative research to further develop, evaluate, or
commercialize ABCB1 genotyping to predict paclitaxel toxicity. Please
contact Betty Tong, PhD at 301-496-0477, tongb@mail.nih.gov for more
information.
Use of Grape Skin Extracts as Anti-Cancer Agents
Description of Technology: The invention describes anti-tumor
effects of extracts from grape skins. Grape skin extract and
derivatives may therefore be useful as preventive or therapeutic agents
against tumor development.
Literature indicates that grape and red wine consumption may be
inversely associated with prostate cancer risk. Moreover, to date there
are no known grape skin extract-associated toxicities described. The
current invention discloses that grape skin extract, or purified
fractions thereof, inhibited metastatic growth in human prostate
transformed cell lines. Specifically, grape skin extract induced
cellular apoptosis via inhibition of the phosphatidylinositol 3-kinase
(PI3-K)/Akt survival pathway.
Historically, anti-tumor effects of grapes were mainly attributed
to resveratrol, a phytoalexin present in grapes, nuts and wild berries.
However, resveratrol's mechanism of anti-tumor action is distinct from
that of grape skin extract, in that it arrests cell cycle division
without significant induction of apoptosis.
The current invention also provides for methods of treating
patients with prostate cancer or persons at risk for developing
prostate cancer with compositions that include grape skin extract or
active anti-tumor fractions thereof.
Development Status: Pre-clinical stage.
Inventors: Tamaro Hudson and Jeffrey E. Green (NCI).
Patent Status: U.S. Provisional Application No. 60/789,181 filed 03
April 2006 (HHS Reference No. E-179-2006/0-US-01).
Licensing Status: Available for non-exclusive or exclusive
licensing.
Licensing Contact: David A. Lambertson, PhD; 301-435-4632;
lambertsond@od.nih.gov.
Collaborative Research Opportunity: The NCI's Laboratory of Cell
Regulation and Carcinogenesis is seeking statements of capability or
interest from parties interested in collaborative research to further
develop, evaluate, or commercialize this technology. Please contact
Patrick Twomey, PhD at 301-496-0477 or twomeyp@mail.nih.gov for more
information.
Dated: August 23, 2006.
Steven M. Ferguson,
Director, Division of Technology Development and Transfer, Office of
Technology Transfer, National Institutes of Health.
[FR Doc. E6-14353 Filed 8-29-06; 8:45 am]
BILLING CODE 4140-01-P
